Literature DB >> 15215124

Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.

Maria D Maciá1, Nuria Borrell, José L Pérez, Antonio Oliver.   

Abstract

Resistance development in Pseudomonas aeruginosa from chronically colonized cystic fibrosis (CF) patients has been linked to the presence of a high proportion of mismatch repair-deficient hypermutable strains. The detection of hypermutable strains by microbiology laboratories may be useful for establishing adequate antimicrobial therapies. In this work, we find that the Etest and disk diffusion can be used as simple methods for the detection and susceptibility testing of hypermutable P. aeruginosa isolates. Strain PAO1 and its hypermutable derivative strain PAODeltamutS were used to standardize the procedure, which was tested with 35 P. aeruginosa isolates from 21 CF patients. Mutation frequencies were estimated by standard methods, and 29% of the isolates were found to be hypermutable. MICs and inhibition zone diameters were determined for ceftazidime, imipenem, meropenem, ciprofloxacin, and tobramycin by using Etest strips and conventional disks, respectively. The presence (or absence) of resistant mutant subpopulations, as well as their relative numbers and the highest MICs for them (or smallest inhibition zone diameters), was recorded. The presence of resistant mutant subpopulations within the inhibition zones of three or more antibiotics clearly identified the strains as hypermutable (they were present in 10 of 10 hypermutable strains and 0 of 25 nonhypermutable strains) with both methods. Additionally, these methods allowed us to differentiate between dual effects of hypermutation in antibiotic resistance, namely, that (i) hypermutable isolates were substantially more resistant than nonhypermutable isolates and that (ii) the resistance of hypermutable isolates was dramatically increased by the presence of resistant mutant subpopulations. This differentiation may be relevant for the design of adequate treatments, since the second effect, in contrast to the first, may be overcome by antibiotic combinations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215124      PMCID: PMC434203          DOI: 10.1128/AAC.48.7.2665-2672.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Escherichia coli mutator genes.

Authors:  J P Horst; T H Wu; M G Marinus
Journal:  Trends Microbiol       Date:  1999-01       Impact factor: 17.079

2.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  Mutator bacteria as a risk factor in treatment of infectious diseases.

Authors:  Antoine Giraud; Ivan Matic; Miroslav Radman; Michel Fons; François Taddei
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  Mismatch repair and the regulation of phase variation in Neisseria meningitidis.

Authors:  A R Richardson; I Stojiljkovic
Journal:  Mol Microbiol       Date:  2001-05       Impact factor: 3.501

5.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

6.  Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; D Larone; J Krzewinski; Z Liu; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

7.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.

Authors:  C K Stover; X Q Pham; A L Erwin; S D Mizoguchi; P Warrener; M J Hickey; F S Brinkman; W O Hufnagle; D J Kowalik; M Lagrou; R L Garber; L Goltry; E Tolentino; S Westbrock-Wadman; Y Yuan; L L Brody; S N Coulter; K R Folger; A Kas; K Larbig; R Lim; K Smith; D Spencer; G K Wong; Z Wu; I T Paulsen; J Reizer; M H Saier; R E Hancock; S Lory; M V Olson
Journal:  Nature       Date:  2000-08-31       Impact factor: 49.962

8.  The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants.

Authors:  Antonio Oliver; Fernando Baquero; Jesús Blázquez
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

9.  Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.

Authors:  C J Henwood; D M Livermore; D James; M Warner
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  26 in total

1.  Influence of Pseudomonas aeruginosa pvdQ gene on altering antibiotic susceptibility under swarming conditions.

Authors:  Lili Wang; Chunling Zhang; Fengyun Gong; Hongtao Li; Xuhua Xie; Chao Xia; Jia Chen; Ying Song; Aixia Shen; Jianxin Song
Journal:  Curr Microbiol       Date:  2011-08-11       Impact factor: 2.188

2.  Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections.

Authors:  M D Maciá; A Mena; N Borrell; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

3.  Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa.

Authors:  David J Waine; David Honeybourne; E Grace Smith; Joanna L Whitehouse; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2008-08-06       Impact factor: 5.948

4.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  Carbapenem-Resistant Pseudomonas aeruginosa in Chronic Lung Infection: Current Resistance Profile and Hypermutability in Patients with Cystic Fibrosis.

Authors:  Mila M Almeida; Meyvianne T Freitas; Tania W Folescu; Monica C Firmida; Ana Paula D'A Carvalho-Assef; Elizabeth A Marques; Robson S Leão
Journal:  Curr Microbiol       Date:  2021-01-06       Impact factor: 2.188

6.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

Authors:  María I Morosini; María García-Castillo; Elena Loza; María Pérez-Vázquez; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

8.  Influence of Pseudomonas aeruginosa pvdQ gene on altering antibiotic susceptibility under swarming conditions.

Authors:  Lili Wang; Chunling Zhang; Fengyun Gong; Hongtao Li; Xuhua Xie; Chao Xia; Jia Chen; Ying Song; Aixia Shen; Jianxin Song
Journal:  Curr Microbiol       Date:  2012-10-23       Impact factor: 2.188

9.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

10.  Role of MexA-MexB-OprM efflux pump system in chronic Pseudomonas aeruginosa pulmonary infection in mice.

Authors:  Fengyun Gong; Weili Zhan; Lili Wang; Ying Song; Mingyou Xing; Jianxin Song
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.